Safety and antimicrobial efficacy of CSL787, a novel nebulized IgG therapy, in patients with bronchiectasis: results from a randomized phase 1 trial

American Journal of Respiratory and Critical Care Medicine 2026 Open access

Read full text
Authors: Damian G. Downey, Ilka Schulze, Andreas Eich, Dave Singh, Michael Larbig, Oliver Vit, Laurent B. Nicolas, Sanjay H. Chotirmall, James D Chalmers
DOI: 10.1093/ajrccm/aamag135
Cited by: 1
References: 10

Abstract

Damian G Downey, M.D, Ilka Schulze, M.D., Ph.D, Andreas Eich, M.D, Dave Singh, M.D, Michael Larbig, M.D., Ph.D, Oliver Vit, Laurent B Nicolas, Ph.D, Sanjay

Fields of Study & Subjects

Cystic Fibrosis Research Advances Asthma and respiratory diseases Respiratory and Cough-Related Research

Publication details

Journal / source
American Journal of Respiratory and Critical Care Medicine
Publisher
Oxford University Press (OUP)
Volume
212
Issue
7
Pages
1643–1646
Publication date
7 April 2026
Language
EN